Search Results - "Masque Soler, N."

Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling by Ococks, E., Frankell, A.M., Masque Soler, N., Grehan, N., Northrop, A., Coles, H., Redmond, A.M., Devonshire, G., Weaver, J.M.J., Hughes, C., Lehovsky, K., Blasko, A., Nutzinger, B., Fitzgerald, R.C., Smyth, E.

“…The incidence of esophageal adenocarcinoma (EAC) is rapidly rising and has a 5-year survival rate of <20%. Beyond TNM (tumor–node–metastasis) staging, no…”
Get full text

Molecular signatures that can be transferred across different omics platforms by Altenbuchinger, M, Schwarzfischer, P, Rehberg, T, Reinders, J, Kohler, Ch W, Gronwald, W, Richter, J, Szczepanowski, M, Masqué-Soler, N, Klapper, W, Oefner, P J, Spang, R

“…Molecular signatures for treatment recommendations are well researched. Still it is challenging to apply them to data generated by different protocols or…”
Get full text

Molecular signatures that can be transferred across different omics platforms by Altenbuchinger, M, Schwarzfischer, P, Rehberg, T, Reinders, J, Kohler, Ch W, Gronwald, W, Richter, J, Szczepanowski, M, Masqué-Soler, N, Klapper, W, Oefner, P J, Spang, R

Get full text

Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in oesophageal adenocarcinoma by Ococks, E., Frankell, A., Masque-Soler, N., Northrop, A., Devonshire, G., Hughes, C., Grehan, N., Smyth, E., Blasko, A., Fitzgerald, R.

Get full text

822PAssessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in oesophageal adenocarcinoma by Ococks, E, Frankell, A, Masque-Soler, N, Northrop, A, Devonshire, G, Hughes, C, Grehan, N, Smyth, E, Blasko, A, Fitzgerald, R

“…Abstract Background Oesophageal cancer is the eighth most frequently diagnosed form of cancer and has a dismal 5-year survival rate of 12%, with Oesophageal…”
Get full text

822P - Assessing the clinical utility of circulating tumour DNA through longitudinal liquid biopsy sampling in oesophageal adenocarcinoma by Ococks, E., Frankell, A., Masque-Soler, N., Northrop, A., Devonshire, G., Hughes, C., Grehan, N., Smyth, E., Blasko, A., Fitzgerald, R.

“…Oesophageal cancer is the eighth most frequently diagnosed form of cancer and has a dismal 5-year survival rate of 12%, with Oesophageal adenocarcinoma (OAC)…”
Get full text

121MO ctDNA and prognosis in resected esophageal adenocarcinoma (EAC) by Ococks, E., Frankell, A.M., Soler, N. Masque, Northrop, A., Coles, H., Grehan, N., Redmond, A., Hughes, C., Devonshire, G., Blasko, A., O. Oesophageal Cancer Clinical Molecular Stratification Consortium, Fitzgerald, R., Smyth, E.

Get full text

83POptimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody by Lakins, M A, Munoz-Olaya, J, Jones, D, Giambalvo, R, Hall, C, Knudsen, A, Masque Soler, N, Pechouckova, S, Goodman, E, Gradinaru, C, Koers, A, Marshall, S, Wydro, M, Wollerton, F, Batey, S, Gliddon, D, Davies, M, Morrow, M, Tuna, M, Brewis, N

Get full text

Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody by Lakins, M.A., Munoz-Olaya, J., Jones, D., Giambalvo, R., Hall, C., Knudsen, A., Masque Soler, N., Pechouckova, S., Goodman, E., Gradinaru, C., Koers, A., Marshall, S., Wydro, M., Wollerton, F., Batey, S., Gliddon, D., Davies, M., Morrow, M., Tuna, M., Brewis, N.

Get full text

Immunohistochemical detection of inhibitor of DNA binding 3 mutational variants in mature aggressive B-cell lymphoma by Szczepanowski, Monika, Masqué-Soler, Neus, Schlesner, Matthias, Haake, Andrea, Richter, Julia, Wagener, Rabea, Burkhardt, Birgit, Kreuz, Markus, Siebert, Reiner, Klapper, Wolfram

Get full text

1572P Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers by Cammarota, A., Devonshire, G., Miremadi, A., Ustaoglu, A., Filippi, B., Zhuang, J.L., Zamani, S., Masqué-Soler, N., Rimassa, L., Fitzgerald, R.C., Smyth, E.

Get full text

SO-12 CLDN18.2 expression in resectable gastroesophageal cancers: Associated clinical and molecular signatures and impact of neoadjuvant chemotherapy on intratumor heterogeneity by Cammarota, A., Devonshire, G., Miremadi, A., Zhuang, L., Zamani, S., Smith, R., Masqué-Soler, N., Ustaoglu, A., Rimassa, L., Fitzgerald, R., Smyth, E.

Get full text